Roche announced it will start Phase 3 studies for aleglitazar, its PPAR co-agonist which is designed to reduce cardiovascular morbidity and mortality in high risk patients with type 2 diabetes. This study, anticipated to start in the second half of 2009, is a cardiovascular outcomes trial designed to assess the potential of once-daily 150 micrograms aleglitazar to reduce cardiovascular mortality, non-fatal myocardial infarction and stroke in type 2 diabetes patients with a recent acute coronary syndrome event.
Aleglitazar is a molecule designed to provide balanced dual PPAR alpha/gamma activation. Specifically, it combines the improvements in peripheral insulin sensitivity (and therefore glycemic control) associated with PPAR gamma activation, with improved management of dyslipidemia, which is commonly associated with PPAR alpha activation.
For more information call (800) 526-6367 or visit www.rocheusa.com.